FDA Actions
The FDA has approved neratinib for the extended adjuvant treatment of early-stage, HER2-positive breast cancer. The drug is a tyrosine kinase inhibitor similar to lapatinib and afatinib. Neratinib is indicated for adults who have been treated with a regimen that includes trastuzumab (Herceptin). The safety and efficacy of neratinib was established in a randomized trial of 2,840 patients with early-stage HER-2 positive breast cancer who had completed treatment with trastuzumab within the previous two years. After two years, invasive disease-free survival was 94.2% with neratinib compared to 91.9% with placebo. The drug commonly causes diarrhea, and loperamide should be administered routinely for the first eight weeks of therapy. Neratinib is marketed as Nerlynx.
The FDA has approved a new combination for the treatment of hepatitis C virus genotypes 1-6 in patients without cirrhosis or with mild cirrhosis. The fixed-dose combination contains two previously approved drugs, sofosbuvir and velpatasvir, along with a new drug, voxilaprevir. It is the first treatment for patients who have been treated with sofosbuvir or NS5A inhibitors. In two Phase III trials, the combination resulted in 96-97% cure rates (no virus detected at 12 weeks) in patients with all genotypes, some of whom had been treated previously. As with all hepatitis C treatment, patients must be screened for hepatitis B to avoid reactivation. The FDA granted this application priority review and breakthrough therapy designations. The new combination is marketed as Vosevi. The drug requires a 12-week course, which will cost about $75,000.
In this section: FDA approves new treatments for breast cancer and hepatitis C.
Subscribe Now for Access
You have reached your article limit for the month. We hope you found our articles both enjoyable and insightful. For information on new subscriptions, product trials, alternative billing arrangements or group and site discounts please call 800-688-2421. We look forward to having you as a long-term member of the Relias Media community.